Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures -- Ignore unavailable to you. Want to Upgrade?

To: ~digs who wrote (1391)	8/23/2005 8:30:10 PM
From: ~digs	Respond to of 7944

CVM .59 stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G CEL-SCI Receives Phase III Clinical Trial Go-Ahead for Cancer Drug RNAI 4.20 stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G TBIO .95 stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G Transgenomic, Inc. provides products and services for the synthesis, purification, and analysis of nucleic acids. The company’s BioSystems products include WAVE automated instrument systems, WAVE associated consumables, and other related consumable products. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. Its Nucleic Acids products include chemical building blocks for nucleic acid synthesis and synthesized nucleic acids. The company’s service offerings include genetic variation discovery and analysis services, novel chemistry development services, and custom synthesis of nucleic acids. It markets its products and services to the life sciences industry to be used in research focused on molecular genetics of humans and other organisms. COR 2.3 stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G -Aug. 23, 2005--Leading scientists from Wake Forest University Baptist Medical Center have demonstrated in a unique primate model that the AMPAKINE® CX717, a member of a novel class of pharmaceuticals under development at Cortex Pharmaceuticals (AMEX: COR - News), improved cognitive performance and also reversed the deleterious effects of sleep deprivation. This research at Wake Forest provided the basis for conducting the Phase II sleep deprivation study in humans, which confirmed CX717 improved wakefulness, memory, cognition and attention without causing systemic stimulation in subjects that were sleep deprived as reported in the Company's May 4, 2005 press release. EFJI 8.5 stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G Aug. 23 /PRNewswire-FirstCall/ -- EFJ, Inc. (Nasdaq: EFJI - News) announced today that its EFJohnson subsidiary has introduced the 3800 Series Project 25 Digital Repeater. These powerful new repeaters provide secure digital communications for first responders operating in a Project 25 trunked network. With coverage in the VHF, UHF, and 800 MHz bands, the 3800 Series repeaters use voice over internet protocol (VoIP) to enable intelligent network communications without costly and complex centralized switching equipment. EFJohnson will be demonstrating the 3800 Series Repeater at the Association of Public Safety Communication Officers International (APCO) 71st Annual Conference and Exposition August 22 - 24 in Denver.